wegovy or tirzepatide Zepbound Beats for Weight Loss in First Head-to-Head Trial Switching between weight-loss medications -

participants will have 17 cl Compare Insulin Icodec and Insulin Glargine, Both in Combination With Mealtime Insulin, in People With Type 2DM previously on basal-bolus therapy Not provided Not provided Anticipated Start Date Not provided Actual Start Date 2021-05-14 Anticipated Date of Last Follow-up 2025-06-15 Estimated Primary Completion Date Not provided Estimated Completion Date Not provided Actual Primary Completion Date 2022-06-16 Actual Completion Date 2022-06-16 Age Cohort Genders Accepts pregnant individuals Unspecified Accepts lactating individuals Unspecified Accepts healthy individuals No Inclusion Criteria: * Male or female aged above or equal to 18 years at the time of signing informed consent

Lih-Brody L, Powell SR, Collier KP, Reddy GM, Kahn E, Weissman GS, Katz S, Floyd RA, McKinley MJ, Fisher SE, and Mullin GE (1996)

The researchers analyzed data from eight randomized controlled trials involving 8,847 participants, most of whom were women (74%) and had obesity (96%)

Importantly, STAT News reports that in reference to todays White House briefing, Novo Nordisk said that Medicare coverage for weight loss will be enabled through a pilot program